RedHill Biopharma

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. It operates through Commercial Operations, and the Research and Development segments. The Commercial Operations segment covers all areas relating to the commercial sales and is being performed by the subsidiary in the U.S. The Research and Development segment includes the study and licensing of therapeutic candidates. Its products include Talicia, Movantik, and Aemcolo. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Authorization of compassionate use granted by the Italian authorities, aided by RedHill’s strategic partner, Cosmo Pharmaceuticals N.V. (SIX: COPN)

RedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in Italy

Compassionate use approved by Israeli Ministry of Health; Additional patients expected to be treated in the coming days

RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use

As of late, it has definitely been a great time to be an investor RedHill Biopharma

Will RedHill Biopharma Continue to Surge Higher?

TEL-AVIV, Israel and RALEIGH, N.C., March  25, 2020  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today provided a business update on proactive measures being taken with regard to the COVID-19 virus outbreak.

RedHill Biopharma Provides Business Update

RedHill recently launched Talicia® in the U.S., calling on gastroenterologists, primary care physicians and other healthcare providers

RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020

Kamada

Vir Biotechnology

Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.

3 Small Biotechs Provide Coronavirus Drug Development Updates

      Phase 2 study evaluating RedHill’s proprietary NCE1 opaganib (Yeliva®, ABC294640) in prostate cancer initiated at Medical University of South Carolina, supported by an NCI grant

RedHill Biopharma Provides Update on Opaganib (Yeliva®)

Talicia  ®   is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high and growing H. pylori resistance to clarithromycin

RedHill Biopharma Announces U.S. Commercial Launch of Talicia® for H.

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2019 Results - Earnings Call Transcript

RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights

RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia® this quarter and the ongoing promotion of Aemcolo®

RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners

RedHill is on track to launch Talicia® in the U.S. in the first quarter of 2020 for the treatment of  H. pylori infection in adults  - - -

RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch

TEL-AVIV, Israel and RALEIGH, N.C., Jan.  21, 2020  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced its decision to discontinue its co-promotion and commercialization agreements for Donnatal® and EnteraGam® to enable a greater focus on its lead commercial products, Talicia® 1 and Aemcolo® 2, and create capacity for additional products.

RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®; Discontinuing Promotion of Legacy Products

Revisiting RedHill Biopharma

TEL-AVIV, Israel and RALEIGH, N.C., Jan.  02, 2020  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has provided Salix Pharmaceuticals Ltd. (Salix) with a notice of termination of their 2014 license agreement and has regained the worldwide exclusive rights to RHB-106, a proprietary encapsulated formulation for bowel preparation, currently under development.

RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106

TEL-AVIV, Israel and RALEIGH, N.C., Dec.  17, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has initiated promotion of Aemcolo® (rifamycin) in the U.S. for the treatment of travelers’ diarrhea caused by non-invasive strains of Escherichia Coli (E. coli) in adults1.

RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers’ Diarrhea

Alteryx

Boot Barn Hlds

Innovative Industrial Properties

SPS Commerce

Wouldn't you like a list of the top growth stocks right now?

How to Screen for the Best Growth Stocks

RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q3 2019 Results - Earnings Call Transcript

TEL-AVIV, Israel and RALEIGH, N.C., Nov.  15, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will voluntarily delist its ordinary shares from trading on the Tel Aviv Stock Exchange (TASE).  

Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange

RedHill And Talicia In H. Pylori Eradication: Just Warming Up

RedHill Biopharma's FDA Approval Moves It Into Large Market Opportunity

TEL-AVIV, Israel and RALEIGH, N.C., Nov.  12, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced the publication of results from the Company’s Phase 3 study with RHB-102 (Bekinda ® )1 in acute gastroenteritis (the GUARD study) in the Journal of the American Medical Association (JAMA) Network Open.

RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA

The FDA just gave the company's latest treatment the green light.

Here's Why RedHill Biopharma Jumped on Monday

RedHill Biopharma Ltd. (NASDAQ: RDHL) shares jumped early on Monday after the firm announced that the U.S.

Meet the Newest FDA Approval in the Fight Against Non-Cardia Gastric Cancer

TEL-AVIV, Israel and RALEIGH, N.C., Nov.  04, 2019  (GLOBE NEWSWIRE) --  RedHill Biopharma Ltd.  (Nasdaq:  RDHL ) (Tel-Aviv Stock Exchange:  RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill expects to launch Talicia in the U.S. in the first quarter of 2020 with its dedicated sales force.

News for RedHill Biopharma Stock (RDHL)